Evogliptin: Phase I started

Tobira began an open-label, U.S. Phase I trial to evaluate 5 mg oral evogliptin with or without 150 mg oral cenicriviroc in 12 healthy volunteers. Tobira has exclusive, worldwide rights to cenicriviroc from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan) (see BioCentury, Aug. 6, 2007). In April, Tobira granted Dong-A exclusive, South Korean rights to cenicriviroc as a single agent or in combination with evogliptin while Dong-A granted Tobira exclusive rights to evogliptin as a single agent or in combination with cenicriviroc in the U.S., Canada, Europe and Australia (see BioCentury, April 26). Cenicriviroc is a dual CC chemokine receptor 5 ( CCR5; CD195) and CCR2 ( CD192) antagonist. ...